Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
Full Text
Peer Reviewed
See detailLong-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study.
Van Gaal, Luc F; Scheen, André ULg; Rissanen, Aila M et al

in European Heart Journal (2008), 29(14), 1761-71

AIMS: Rimonabant, the first selective cannabinoid type 1 receptor blocker, has been shown to produce weight loss and improvements in several cardiometabolic risk factors over 1 year. We report the 2 year ... [more ▼]

AIMS: Rimonabant, the first selective cannabinoid type 1 receptor blocker, has been shown to produce weight loss and improvements in several cardiometabolic risk factors over 1 year. We report the 2 year efficacy and tolerability data of rimonabant. METHODS AND RESULTS: Patients with a body mass index > or =30 or >27 kg/m(2) with treated/untreated hypertension, dyslipidaemia, or both, were randomized to double-blind treatment with placebo, rimonabant 5 or 20 mg once daily plus a calorie-restricted diet for 2 years. Weight loss from baseline to 2 years in the intention-to-treat population was significantly greater with rimonabant 20 mg (mean +/- SD: -5.5 +/- 7.7 kg; P < 0.001) and 5 mg (-2.9 +/- 6.5 kg; P = 0.002) than placebo (-1.2 +/- 6.8 kg). Rimonabant 20 mg produced significantly greater improvements than placebo in waist circumference, high-density lipoprotein cholesterol, triglycerides, fasting glucose and insulin levels, insulin resistance, and metabolic syndrome prevalence. Rimonabant 20 mg produced clinically meaningful improvements in all Impact of Weight on Quality of Life-Lite questionnaire domain scores at 2 years. Rimonabant was generally well tolerated and rates of adverse events, including depressed mood disorders and disturbances were similar to placebo during year 2. Proportions of patients with clinically significant depression (Hospital Anxiety and Depression Scale score >11) were similar in all treatment groups. CONCLUSION: Rimonabant 20 mg over 2 years promoted clinically relevant and durable weight loss and improvements in cardiometabolic risk factors. [less ▲]

Detailed reference viewed: 19 (1 ULg)
Peer Reviewed
See detailLong-term effect on plasma, meat and milk selenium and blood glutathion peroxydase of feeding selenium-enriched barley and haylage to Belgian Blue cows, calves and fattened bulls
de Behr, V.; Marche, C.; Coenen, M. et al

in Proceedings of 7th Conference of the European Society of Veterinary and Comparative Nutrition (2003)

Detailed reference viewed: 9 (3 ULg)
Peer Reviewed
See detailLong-term effects of androgen treatment on fear reactions in ewes.
Bouissou, Marie-France; Vandenheede, Marc ULg

in Hormones & Behavior (1996), 30

Detailed reference viewed: 14 (3 ULg)
Full Text
Peer Reviewed
See detailLong-term Effects of Avocado/Soybean Unsaponifiable on Human Chondrocytes Metabolism
Henrotin, Yves ULg; Sanchez, Christelle ULg; Deberg, Michelle ULg et al

in Clinical Rheumatology (2001), 20(5), 45

Detailed reference viewed: 11 (2 ULg)
Full Text
Peer Reviewed
See detailLong-term Effects of Avocado/Soybean Unsaponifiable on Human Chondrocytes Metabolism
Henrotin, Yves ULg; Sanchez, Christelle ULg; Deberg, Michelle ULg et al

in Osteoarthritis and Cartilage (2001), 9(supplB), 25

Detailed reference viewed: 40 (7 ULg)
Full Text
Peer Reviewed
See detailLong-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial.
Kahan, Andre; Uebelhart, Daniel; De Vathaire, Florent et al

in Arthritis and Rheumatism (2009), 60(2), 524-33

OBJECTIVE: To assess the long-term effects of chondroitins 4 and 6 sulfate (CS) on the radiographic progression of, and symptom changes associated with, knee osteoarthritis (OA). METHODS: We performed an ... [more ▼]

OBJECTIVE: To assess the long-term effects of chondroitins 4 and 6 sulfate (CS) on the radiographic progression of, and symptom changes associated with, knee osteoarthritis (OA). METHODS: We performed an international, randomized, double-blind, placebo-controlled trial in which 622 patients with knee OA were randomly assigned to receive either 800 mg CS (n = 309 patients) or placebo (n = 313 patients) once daily for 2 years. Radiographs of the target knee, using the Lyon schuss view, were obtained at the time of enrollment and at 12, 18, and 24 months. The minimum joint space width (JSW) of the medial compartment of the tibiofemoral joint was assessed by digital image analysis. The primary outcome was the loss in minimum JSW over 2 years. RESULTS: The intent-to-treat analysis demonstrated a significant reduction (P < 0.0001) in minimum JSW loss in the CS group (mean +/- SEM -0.07 +/- 0.03 mm) as compared with the placebo group (-0.31 +/- 0.04 mm). The percentage of patients with radiographic progression > or =0.25 mm was significantly reduced in the CS group compared with the placebo group (28% versus 41% [P < 0.0005]; relative risk reduction 33% [95% confidence interval 16-46%]). The number of patients needed to treat was 8 (95% confidence interval 5-17). Pain improved significantly faster in the CS group than in the placebo group (P < 0.01). There were no differences in safety between groups. CONCLUSION: The long-term combined structure-modifying and symptom-modifying effects of CS suggest that it could be a disease-modifying agent in patients with knee OA. [less ▲]

Detailed reference viewed: 38 (2 ULg)
Full Text
Peer Reviewed
See detailLong-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial
Reginster, Jean-Yves ULg; Deroisy, Rita ULg; Rovati, Lucio C et al

in Lancet (2001), 357

BACKGROUND: Treatment of osteoarthritis is usually limited to short-term symptom control. We assessed the effects of the specific drug glucosamine sulphate on the long-term progression of osteoarthritis ... [more ▼]

BACKGROUND: Treatment of osteoarthritis is usually limited to short-term symptom control. We assessed the effects of the specific drug glucosamine sulphate on the long-term progression of osteoarthritis joint structure changes and symptoms. METHODS: We did a randomised, double-blind placebo controlled trial, in which 212 patients with knee osteoarthritis were randomly assigned 1500 mg sulphate oral glucosamine or placebo once daily for 3 years. Weightbearing, anteroposterior radiographs of each knee in full extension were taken at enrolment and after 1 and 3 years. Mean joint-space width of the medial compartment of the tibiofemoral joint was assessed by digital image analysis, whereas minimum joint-space width--ie, at the narrowest point--was measured by visual inspection with a magnifying lens. Symptoms were scored by the Western Ontario and McMaster Universities (WOMAC) osteoarthritis index. FINDINGS: The 106 patients on placebo had a progressive joint-space narrowing, with a mean joint-space loss after 3 years of -0.31 mm (95% CI -0.48 to -0.13). There was no significant joint-space loss in the 106 patients on glucosamine sulphate: -0.06 mm (-0.22 to 0.09). Similar results were reported with minimum joint-space narrowing. As assessed by WOMAC scores, symptoms worsened slightly in patients on placebo compared with the improvement observed after treatment with glucosamine sulphate. There were no differences in safety or reasons for early withdrawal between the treatment and placebo groups. INTERPRETATION: The long-term combined structure-modifying and symptom-modifying effects of gluosamine sulphate suggest that it could be a disease modifying agent in osteoarthritis. [less ▲]

Detailed reference viewed: 40 (10 ULg)
Full Text
Peer Reviewed
See detailLong-term effects of JL 13, a potential atypical antipsychotic, on Ionotropic glutamate receptors
Tarazi, Frank I.; Moran-Gates, Taylor; Gardner, Matthew P. et al

in Journal of Molecular Neuroscience (2007), 32(3), 192-198

Changes in ionotropic glutamate (Glu) N-methyl-D-aspartic acid (NMDA), and 2-amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl)propionic acid (AMPA) receptors in rat forebrain regions were autoradiographically ... [more ▼]

Changes in ionotropic glutamate (Glu) N-methyl-D-aspartic acid (NMDA), and 2-amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl)propionic acid (AMPA) receptors in rat forebrain regions were autoradiographically quantified after continuous infusion of JL 13 [(5-(4-methylpiperazin-1-yl)-8-chloro-pyrido[2,3-b][1,5]benzoxazepine furnarate] for 28 days using osmotic minipumps, and compared to the effects of representative typical (haloperidol) and atypical (clozapine, olanzapine, and risperidone) antipsychotic drugs from previous studies. Similar to other atypical and not typical antipsychotics, JL 13 decreased labeling of NMDA receptors in medial and lateral caudate-putamen (CPu; by 40%). These findings indicate that downregulation of NMDA receptors by JL 13 and other atypical antipsychotic agents in CPu may contribute to their low risk of extrapyramidal side effects. In addition, and similar to olanzapine and risperidone, JL 13 increased AMPA receptor binding in CPu (by 42%). Changes in AMPA receptors may contribute to psychopharmacological properties of JL 13 and other atypical agents. Similar to clozapine, JL 13 did not alter levels of NMDA and AMPA receptors in hippocampus and entorhinal cortex. Long-term effects of JL 13 on ionotropic Glu receptors, as well as on other dopamine and serotonin receptors, support the atypical antipsychotic profile of this novel agent. [less ▲]

Detailed reference viewed: 26 (3 ULg)
Full Text
Peer Reviewed
See detailLong-term effects of JL 13, a potential atypical antipsychotic, on rat dopamine and serotonin receptor subtypes
Moran-Gates, Taylor; Massari, Carla; Graulich, Amaury ULg et al

in Journal of Neuroscience Research (2006), 84(3), 675-682

Changes in dopamine (DA) D-1, D-2, D-3, and D-4 receptors and serotonin 5-HT1A and 5-HT2A receptors in rat forebrain regions were autoradiographically quantified after continuous infusion of JL 13 [(5-(4 ... [more ▼]

Changes in dopamine (DA) D-1, D-2, D-3, and D-4 receptors and serotonin 5-HT1A and 5-HT2A receptors in rat forebrain regions were autoradiographically quantified after continuous infusion of JL 13 [(5-(4-methylpiperazin-1-yl)8-chloro-pyrido[2,3-b][1,5]benzoxazepine fumarate] for 28 days with osmotic minipumps and compared with the effects of other typical (fluphenazine) and atypical (clozapine, olanzapine, and risperidone) antipsychotic drugs from previous studies. Similar to other typical and atypical antipsychotics, JL 13 increased labeling of D2 receptors in medial prefrontal cortex (MPC) and hippocampus (HIP) and D-4 receptors in nucleus accumbens (NAc), caudate-putamen (CPu), and HIP In addition, JL 13 increased 5-HT1A and decreased 5-HT2A receptors in MPC and dorsolateral frontal cortex (DFC), an effect shared by atypical antipsychotics, and may contribute to their psychopharmacological properties. Clozapine and JL 13, but not other antipsychotics, spared D2 receptors in CPu, which may reflect their ability to induce minimal extrapyramidal side effects. In addition, JL 13 but not other typical and atypical antipsychotic drugs increased abundance of D, receptors in CPu and NAc. JL 13 as well as other antipsychotic agents did not alter levels of forebrain D3 receptors. An atypical-like profile of JL 13 on DA and 5-HT receptor subtypes should encourage further development of this compound as a novel atypical anti psychotic drug. (c) 2006Wiley-Liss, Inc. [less ▲]

Detailed reference viewed: 81 (5 ULg)
Full Text
Peer Reviewed
See detailLong-term Effects of Nonsteroidal Antiinflammatory Drugs on Human Chondrocytes in Alginate Beads
Sanchez, Christelle ULg; Deberg, Michelle ULg; Reginster, Jean-Yves ULg et al

in Osteoarthritis and Cartilage (2001), 9(supplB), 32

Detailed reference viewed: 30 (10 ULg)
Full Text
Peer Reviewed
See detailLong-term Effects of Nonsteroidal Antiinflammatory Drugs on Human Chondrocytes in Alginate Beads
Sanchez, Christelle ULg; Deberg, Michelle ULg; Reginster, Jean-Yves ULg et al

in Annals of the Rheumatic Diseases (2001), 60(suppl1), 284

Detailed reference viewed: 18 (6 ULg)
Peer Reviewed
See detailLong-term effects of oral estradiol and dydrogesterone on carbohydrate metabolism in postmenopausal women.
Gaspard, Ulysse ULg; Wery, Olivier ULg; Scheen, André ULg et al

in Climacteric : The Journal of the International Menopause Society (1999), 2(2), 93-100

OBJECTIVE: To determine in postmenopausal women the long-term effects on carbohydrate metabolism of the administration of oral micronized 17 beta-estradiol (2 mg/day continuously) and cyclical ... [more ▼]

OBJECTIVE: To determine in postmenopausal women the long-term effects on carbohydrate metabolism of the administration of oral micronized 17 beta-estradiol (2 mg/day continuously) and cyclical dydrogesterone (10 mg/day for 14 days per 28-day cycle). METHODS: A 2-year open-label prospective, non-comparative study was carried out of 13 healthy postmenopausal women receiving cyclical estradiol and dydrogesterone and serving as their own controls. Concentrations of blood glucose, plasma insulin, C-peptide, glucagon and free fatty acids (FFAs) were determined before treatment (base-line) and at 6, 12 and 24 months of hormone replacement therapy under fasting conditions and during a standard 75-g, 3-h, oral glucose tolerance test (OGTT). RESULTS: Fasting blood glucose levels were unchanged throughout the study, and the mean areas under the curves (AUCs) for glucose response increased slightly but non-significantly versus baseline; fasting plasma insulin levels tended a decrease, and AUCs for insulin responses to the glucose load fell by 23% from baseline (not significant); fasting C-peptide levels and AUCs were unchanged; plasma glucagon fasting levels and responses were in the normal range and stable throughout the study; and plasma FFA fasting levels decreased significantly, as well as FFA AUCs during OGTTs, at the 12th and 24th months of the study. CONCLUSIONS: During a 2-year treatment with oral estradiol and cyclical dydrogesterone, a direct progesterone derivative, tolerance to glucose was unchanged, fasting plasma insulin and insulin response to repeated glucose loads were decreased, and C-peptide levels remained unchanged, indicating a potential improvement in insulin sensitivity and clearance, as in younger women; additionally, a slightly enhanced antilipolytic activity of insulin was observed. [less ▲]

Detailed reference viewed: 48 (1 ULg)
Full Text
Peer Reviewed
See detailLong-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 phase iii trials.
Steigbigel, Roy T; Cooper, David A; Teppler, Hedy et al

in Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America (2010), 50(4), 605-12

BENCHMRK-1 and -2 are ongoing double-blind phase III studies of raltegravir in patients experiencing failure of antiretroviral therapy with triple-class drug-resistant human immunodeficiency virus ... [more ▼]

BENCHMRK-1 and -2 are ongoing double-blind phase III studies of raltegravir in patients experiencing failure of antiretroviral therapy with triple-class drug-resistant human immunodeficiency virus infection. At week 96 (combined data), raltegravir (400 mg twice daily) plus optimized background therapy was generally well tolerated, with superior and durable antiretroviral and immunological efficacy, compared with optimized background therapy alone. [less ▲]

Detailed reference viewed: 18 (2 ULg)
Full Text
Peer Reviewed
See detailLong-term efficacy and safety of strontium ranelate in postmenopausal osteoporotic women: results over 10 years
Reginster, Jean-Yves ULg; Kaufman, Jean-Marc; Devogelaer, Jean-Pierre et al

in Osteoporosis International (2011, March), 22(Suppl.1), 110-111

Detailed reference viewed: 40 (6 ULg)